0
Sutro Biopharma, Inc. Banner Image

Sutro Biopharma, Inc. has reached its limit for free report views

Work for Sutro Biopharma, Inc.? Upgrade Your Profile and unlock all your annual reports.

Sutro Biopharma, Inc.

  • Ticker STRO
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Sutro Biopharma, Inc. Logo Image
  • 51-200 Employees
  • Based in South San Francisco, California
Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company. Using precise protein engineering and rational design, Sutro is advancing next-generation oncology therapeutics. Sutro's proprietary and integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+™, led to the discovery of STRO-001More and STRO-002, Sutro's first two internally-developed antibody-drug conjugates, or ADCs. STRO-001 is a CD74 ADC currently being investigated in a Phase I study of patients with advanced B-cell malignancies, including multiple myeloma and non-Hodgkin's lymphoma. STRO-001 was granted Orphan Drug Designation by the FDA for multiple myeloma in October 2018. STRO-002 is an anti-folate receptor alpha (FoIRα) ADC, currently being investigated in a Phase I study of patients with ovarian and endometrial cancers. This is the second product candidate to be evaluated in clinical trials resulting from Sutro's XpressCF+™ technology platform.
Sutro Biopharma, Inc.

Most Recent Annual Report

Sutro Biopharma, Inc. MOST RECENT 2020 Annual Report and Form 10K

Report Locked. Sutro Biopharma, Inc. has reached its limit for free report views.

Older/Archived Annual Reports